2-Aminopyrimidine in Anticancer Drug Discovery: A Bibliometric and Complementary Literature Analysis
Open Access
- 8 October 2026
- journal article
- Published by SAGE Publications in Journal of Applied Pharmaceutical Science
- Vol. 16 (10) , 1012-1030
Abstract
2-Aminopyrimidine (2-AP)–based compounds have gained considerable attention for their anticancer potential, demonstrated by their ability to inhibit tumor growth across diverse malignancies in preclinical models, and several candidates have also progressed into the clinical management of patients with cancer. In this study, a bibliometric analysis was conducted using Scopus to evaluate the research landscape of 2-AP. Two complementary datasets were analyzed: a general dataset including 793 publications from 1990 to 2025, and a cancer-focused dataset including 81 publications from 2004 to 2025. Data were analyzed using VOSviewer to identify trends in publication output, research areas, and collaboration networks. The results revealed a significant increase in research output since 2004, with most studies concentrated in the fields of Chemistry (40.2%), Pharmacology, Toxicology and Pharmaceutics (14.5%), and Biochemistry, Genetics and Molecular Biology (14.2%). Enzymatic assays, X-ray crystallographic studies, and molecular docking approaches assessing the anticancer activities of 2-AP analogs have emerged as a key research focus. Geographically, China, India and the United States were identified as the most productive contributors. These findings highlight the increasing importance of the 2-AP scaffold as a structural motif for incorporation into novel molecules in the context of oncology drug development.Keywords
This publication has 56 references indexed in Scilit:
- Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatmentBioorganic Chemistry, 2024
- Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure‐Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor)The Journal of Clinical Pharmacology, 2024
- 2-Aminopyrimidine2023
- Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3)Bioorganic Chemistry, 2020
- The kinase inhibitor BX795 suppresses the inflammatory response via multiple kinasesBiochemical Pharmacology, 2020
- 2‐Aminopyrimidines2018
- Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)ChemMedChem, 2016
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabineInvestigational New Drugs, 2014
- Selective TBK1/IKKi dual inhibitors with anticancer potencyInternational Journal of Cancer, 2013
- Software survey: VOSviewer, a computer program for bibliometric mappingScientometrics, 2009